超百亿美元大单却带不动股价 创新药BD催化剂失灵?

第一财经
Oct 29, 2025

仅仅一两个月前,一项重磅BD(商务拓展)协议,就足以让一家创新药企的股价平地起飞。如今,即便收获了金额百亿美元以上的超“大单”,创新药企业的股价仍旧低迷。近期,普瑞金、奥赛康、海和药物、维立志博、翰森制药等5家国内药企纷纷宣布达成了商务拓展(BD)交易,但并没有给创新药二级市场带来什么提振。Wind数据显示,港股通创新药指数从10月9日开始震荡下行,从1240点上方一路走低至1110点。“涨不动”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10